appropriateness and identify possible drug interactions that might occur after surgery. However, while substantial attention is invested in the evaluation clinic to identify traditional risk factors, we often overlook medications that might be markers for serious conditions, lack of adherence, or other behaviors that may affect patient and allograft survival. Until recently, use of pharmaceutical claims to quantitatively inform expectations for clinical outcomes before and after transplant and living organ donation has not been described.
Opioid analgesics serve an important role in the management of acute and chronic pain, but recognition of an "epidemic" of complications related to the over-prescribing, misuse, and inherent potential toxicity of prescription opioids is growing. 4, 5 The daily news resounds with descriptions of this epidemic and the national surge in opioid-related deaths. [6] [7] [8] Presurgical use of opioid analgesics is increasingly recognized as a predictor of postoperative complications and resource utilization in diverse populations, including those undergoing general, orthopedic, and liver transplant surgeries, as well as living donor nephrectomy procedures. [9] [10] [11] [12] Concerns about opioid-related toxicity are even greater in patients with endstage organ failure due to altered drug-protein binding, metabolism, and excretion, leading to accumulation of parent agents and potentially toxic metabolites. 13, 14 Patients who use high levels of opioids may also have an increased risk of nonadherence to prescribed care.
Recently, we developed a novel integrated database incorporating dispensed prescription records from a large pharmaceutical claims warehouse with the national transplant registry data.
Using these linked data, we identified adverse clinical outcomes in transplant recipients who filled prescription opioids before surgery, including increased risk of death and graft failure after liver transplant, 11 and increased risk of readmission after living donor nephrectomy. 12 Among samples of kidney transplant recipients,
2005-2010, we found that compared with those who did not fill opioids, patients with the highest level of pretransplant opioid use had a 63% increased risk of death and a 41% increased risk of all-cause graft failure, 15 and increase risks of posttransplant complications, such as cardiovascular, respiratory, or neurological events. 16 These findings resonate with a new report of graded increases in death rates with higher prescription opioid doses in dialysis patients. 17 To address the effect of America's opioid epidemic on kidney transplant recipients, we extended our previous work examining associations between pretransplant opioid use and transplant outcomes by studying a larger, more contemporary cohort of recipients who underwent kidney transplant through 2015. In addition,
we examined relationships of pretransplant opioid use with opioid fills in the year after transplant, and associations of posttransplant use with subsequent outcomes. We hypothesized that pre-and posttransplant prescription opioid use are associated with patient and graft outcomes after kidney transplant, and risk may increase with higher levels of use.
| ME THODS

| Data sources
We conducted a retrospective cohort study using linked healthcare databases in the U.S. to ascertain patient characteristics, pharmacy de-identification software employs multiple encryption algorithms in succession to guarantee that the resulting "token" containing encrypted patient identifiers can never be decrypted. However, the algorithm yields the same results for a given set of data elements, such that linkages by unique anonymous tokens are possible.
All direct identifiers were removed before the final dataset was available for analysis. Because of the large sample size, the anonymity of the patients studied, and the nonintrusive nature of the research, a waiver of informed consent was granted per the Department of 
| Population and covariates
We included kidney transplant recipients who underwent transplant between 2007 and 2015 and who had one year of pretransplant pharmacy fill records in SHS. We examined a subgroup of the cohort with available data in the records to ascertain prescription opioid use in the year before and after transplant. Transplant recipient clinical and demographic characteristics, and characteristics of the donated organ and other transplant factors, were defined by the
OPTN Transplant Candidate Registration and Transplant Recipient
Registration forms (Table 1) .
Pharmacy fills for opioid analgesics in the year before and after transplant were ascertained from the SHS records. Opioid use was normalized to morphine equivalents (ME), according to conversion ratios, as previously described (Table S1) . 7, 8 Pre-and posttransplant ME were aggregated, separately within each period, for each recipient and expressed as dose (mg) of ME exposure over the year. We ranked annual ME exposure among recipients who filled opioid prescriptions by levels as: level 1, >0 to 300 mg; level 2, 301-600 mg; level 3, 601-1000 mg; and level 4, >1000 mg per year, similar to previous methods. 11, 12, 15, 16 We performed sensitivity analyses considering opioid filling patterns within 6 months and in months 7-12 prior to transplant.
| Outcome measurements
The primary outcomes were all-cause mortality and graft failure.
Graft failure was defined as return to maintenance dialysis or retransplant. All-cause graft failure included graft loss due to patient were quantified by multivariate Cox regression including adjustment for recipient, donor, and transplant clinical factors. In all outcome analyses, we interpreted two-tailed P < .05 as statistically significant.
| Statistical analyses
| RE SULTS
| Baseline characteristics of kidney transplant recipients
A STROBE checklist for the study is provided in 
| Patterns of opioid use before and after transplant
We examined a subgroup of the cohort (n = 58,154, 77.1%) with available data in the pharmacy records to determine prescription opioid use in the year before and after transplant. Overall, 70.5% (Table S4) . Age 31-44 years was also associated with posttransplant opioid use. Figure 2 ). Risk relationships persisted with extension of observation time over five years after the first anniversary ( Figure S2 
| D ISCUSS I ON
The national epidemic of prescription opioid use is affecting patients across domains of care. Because of high-frequency use and potential for increased risks due to altered drug metabolism, prescription opioids are a particular concern among populations with reported moderate-severe pain. 22 A new study of prescription fills among Medicare-insured dialysis patients found that more than 60% filled at least one opioid prescription every year. 17 Our results support the notion that pretransplant prescription opioid use is not only prevalent in this unique patient population, but it also has significant implications for posttransplant patient and graft survival.
Patients who used prescription opioids pretransplant were likely to continue use posttransplant. In our current study, 60% of recipients with the highest level of pretransplant prescription opioid use continued high levels of use posttransplant. Possibly, ongoing prescription opioid use posttransplant is due to persistent pain. In a cross-sectional study of 164 hemodialysis patients and 114 stable deceased donor kidney transplant recipients, prevalence of reported pain was similar (63% vs. 62%), suggesting that successful kidney transplant does not reduce the prevalence of chronic pain in patients with ESRD. 24 Similarly, at one U.S. center, pretransplant opioid 
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use was the strongest predictor of posttransplant use. 25 Due to the nature of our available data sources, we were unable to determine the reason for ongoing prescription opioid use. Thus, it is unknown whether kidney transplant recipients experience persistent pain posttransplant requiring opioid treatment, or whether pain management was not reassessed posttransplant and the pretransplant regimen was continued. While the former may represent appropriate management, efforts should be made to prevent the latter and to review and attempt to wean opioids that are no longer needed.
In our study, prescription opioid use in the first year after transplant had a strong, graded associated with increased risk of death and graft failure in the subsequent year, and the highest level of use predicted two-fold increased risk of death, 35% increased risk of deathcensored graft failure, and 68% increased risk of all-cause graft failure compared with non-use. Poorer outcomes with opioid use in kidney transplant recipients may reflect comorbidity associated with chronic pain, such as diabetes mellitus, or psychiatric conditions such as depression. 26 In addition, opioid use may be related to riskier patient behaviors, such as noncompliance with appointments or immunosuppressive medications, which may increase the risk of adverse posttransplant outcomes. 27 At one center, Kulshrestha et al.
found that opioid use in the first year was associated with increased readmission rates but no difference in rejection rates. 25 Further research is needed to understand the factors contributing to the increased risk of death and graft failure in kidney transplant recipients who require opioids for ongoing pain management.
Regardless of the mechanisms of association, identification of novel markers of posttransplant outcomes is timely and can help transplant programs assess and manage risk at a programmatic level.
Transplantation in the U.S. is an increasingly regulated field with a high level of public reporting. Transplant centers are graded for recipient and graft survival using risk-adjusted equations developed by SRTR to predict expected one-year posttransplant patient and graft survival. 28 Importantly, SRTR equations do not adjust for pain Our study has a number of strengths, including use of a novel integrated national data registry that allows identification of prescription opioid fills. Electronic prescription fills have been shown
to be highly accurate and may better represent the burden of opioid use compared with self-reported questionnaires. 29, 30 We used these data to understand the implications of pre-and posttransplant prescription opioid use for clinically relevant outcomes in a large cohort of kidney transplant recipients. We were also able to describe patterns of opioid use among recipients before and after transplant.
There are limitations to our study. We describe associations but are unable to prove causation between opioid use and adverse clinical outcomes. While use of pharmacy electronic records to identify prescription fills may be more accurate than self-report, opioid use and its impact may be underestimated as we were unable to account for illicit drug use, "pharmacy shopping" behaviors, or prescription were unable to determine whether opioid use pre-and posttransplant is continually monitored and managed for appropriateness.
In conclusion, our results reinforce the growing concern about the outcome implications of prescription opioids, particularly in unique patient populations. We identified an increased risk of death and graft failure in kidney transplant recipients with evidence of high-level prescription opioid use before or after surgery.
Transplant centers should assess opioid use in candidates being evaluated for transplant and reassess ongoing use after transplant. 
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